Successful treatment of hepatic oligometastases with stereotactic ablative radiotherapy and radiofrequency ablation in an anaplastic lymphoma kinase fusion-positive lung cancer patient

J Med Radiat Sci. 2016 Mar;63(1):67-70. doi: 10.1002/jmrs.144. Epub 2015 Oct 3.

Abstract

Local ablative therapy with stereotactic ablative radiotherapy may improve survival in oncogene-addicted lung cancer patients with extracranial oligometastatic disease treated with targeted therapies. There is limited data on the use of radiofrequency ablation (RFA) in this same setting. We present a case of an anaplastic lymphoma kinase (ALK)-positive lung cancer patient with hepatic oligometastatic progression who was successfully treated with both stereotactic ablative radiation and RFA while continuing with an ALK inhibitor.

Keywords: Lung cancer; oligometastases; radiofrequency ablation; stereotactic ablative radiotherapy.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology*
  • Female
  • Humans
  • Liver Neoplasms / radiotherapy*
  • Liver Neoplasms / secondary
  • Liver Neoplasms / surgery
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology*
  • Middle Aged
  • Pulsed Radiofrequency Treatment*
  • Radiosurgery*
  • Receptor Protein-Tyrosine Kinases / genetics

Substances

  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases